BELLE Capital
VC Fund
Douglas, United States
BELLE Capital is an early stage angel fund for building companies.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries BELLE Capital invests in
Stages BELLE Capital invests in
Countries BELLE Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Annette Cress
|
|||
Barbara Boxer
|
|||
Irene G. Hrusovsky
|
|||
Michelle Hanks
|
|||
Daniel DeWolf
|
Investment Focus
Industry
- Health Care 2 (25%)
- Life Science 2 (25%)
- Biotechnology 2 (25%)
- Manufacturing 2 (25%)
- Consumer Electronics 2 (25%)
Stage
- Seed 4 (50%)
- Series A 3 (38%)
- Series B 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Annette Cress
Controller
|
Controller | Total investments: 0 | Find email | |
|
Barbara Boxer
Investment Partner Belle Capital Fund
|
Investment Partner Belle Capital Fund | Total investments: 0 | Find email | |
|
Irene G. Hrusovsky
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Michelle Hanks
CPA
|
CPA | Total investments: 0 | Find email | |
|
Daniel DeWolf
General Counsel
|
General Counsel | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TO THE MARKET
|
TO THE MARKET is an innovative platform powering the ethical and sustainable supply chain for some of the world’s largest companies. Facing intense and rising demand for operational transparency, our clients rely on our proprietary digitized vendor scoring, procurement workflows, automated reporting, and more. | $5M / Series A / Oct 05, 2021 | |
|
TO THE MARKET
|
TO THE MARKET is an innovative platform powering the ethical and sustainable supply chain for some of the world’s largest companies. Facing intense and rising demand for operational transparency, our clients rely on our proprietary digitized vendor scoring, procurement workflows, automated reporting, and more. | Seed / Dec 01, 2019 | |
Opus Genetics(formerly Ocuphire Pharma)
|
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $5M / Seed / Jul 22, 2019 | |
Vyv
|
Vital Vio offers a new class of antimicrobial light for infection and germ control through safe, continuous LED products. Our goal is to protect as many people and places from germs as possible with our products which can be utilized anywhere a light can fit. We service customers in food processing, healthcare, industrial/commercial as well asa licensing model for consumer and residential products. | Seed / Jan 25, 2018 | |
Joylux
|
Joylux is a health and wellness company that specializes in women's health and wellness. The company is committed to finding scientific solutions that are noninvasive, effective, and affordable to help improve all aspects of a woman’s intimate life. The company was founded in 2013 and headquartered in Seattle, Washington. | $5M / Series A / Dec 22, 2017 | |
Digsite
|
Digsite® is a SaaS platform for social-media style market research that allows users to quickly engage consumers to build and optimize early ideas for new product concepts, marketing programs, or customer experiences. Marketers, researchers and agencies use Digsite to learn and iterate with consumers over 24 hours or more. The result is better,faster business decisions.Digsite is at the forefront of qualitative market research automation, making it possible to recruit, set-up and launch a social-media style research community with up to 100 consumers in one day or less. The platform looks and feels familiar – like the social media sites people use everyday on their smart phones, tablets and computers. However, Digsite offers a turn-key interface and advanced automation to make it fast and easy to identify and recruit participants, create a community with expert-designed activities, manage participation & rewards, and download summary reporting. It also embeds proprietary research-specific tools to manage conversations, build surveys, mark-up images, capture video and more. | $775K / Seed / Jun 25, 2015 | |
CardiaLen
|
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition. It was founded in 2008 and headquartered in Minneapolis, Minnesota. | $1.5M / Series B / Mar 26, 2015 | |
Current Motor Company
|
Current Motor fills the unmet need for fast, fun, affordable, zero-emission, electric vehicles (EVs). Current Motor develops and manufactures all-electric maxi-scooters for the Americas, made in Michigan. The company’s EVs use no gas, produce no emissions and create no maintenance hassles. Their maxi-scooters offer speeds up to 70 MPH and arange of up to 50 miles. They charge from a standard 110V household outlet in 5 hours. Backed by BELLE Capital, the State of Michigan and other private equity investors, please visit www.currentmotor.com for more information.They are shipping Test Pilot (beta) bikes with full production maxi-scooters scheduled to ship at the end of the 2011. | $700K / Series A / May 02, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BELLE Capital invest in?
BELLE Capital invests primarily in Health Care, Life Science and Biotechnology startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BELLE Capital?
Public channels for BELLE Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BELLE Capital?
The team at BELLE Capital includes Annette Cress (Controller), Barbara Boxer (Investment Partner Belle Capital Fund) and Irene G. Hrusovsky (Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
